United States: President Trump Tariffs on Patented Pharmaceuticals Under Section 232

Why It Matters

The tariffs reshape the cost structure of U.S. drug imports, pressuring multinational pharma to relocate manufacturing or renegotiate pricing, while signaling broader security‑driven trade actions in the health‑care arena.

Key Takeaways

• 100% tariff on most patented drug imports starts July 31, 2026.
• EU, Japan, Korea, Switzerland/Liechtenstein face 15% tariff; UK 10%.
• Onshoring or MFN pricing agreements can cut tariffs to 20% or zero.
• Exemptions include orphan drugs, cell therapies, nuclear medicines, and medical countermeasures.

Pulse Analysis

The Section 232 proclamation marks a decisive shift in U.S. trade policy, using national‑security language to justify steep duties on patented medicines. By targeting high‑value, IP‑protected drugs, the administration aims to reduce reliance on foreign supply chains that could be vulnerable in geopolitical crises. Companies that depend on Asian or European APIs now face a default 100% tariff, effectively doubling landed costs unless they qualify for reduced rates. This creates immediate pressure to reassess sourcing strategies, accelerate onshoring projects, or seek exemptions for critical therapies.

For multinational pharma, the tiered tariff structure introduces a complex calculus. Nations with existing trade agreements, such as the EU, Japan, South Korea, and Switzerland/Liechtenstein, enjoy a 15% duty, while the United Kingdom benefits from a 10% rate that could fall to zero under a future pricing pact. More attractive are the onshoring and MFN pricing incentives, which can lower tariffs to 20% or eliminate them entirely through 2029. These provisions reward firms that commit capital to U.S. manufacturing and align domestic drug prices with federal benchmarks, potentially reshaping global R&D investment flows and accelerating domestic production capacity.

Beyond immediate cost implications, the proclamation signals a broader trend of security‑linked trade measures across the health sector. Ongoing Section 232 reviews of personal protective equipment, medical devices, and robotics suggest that additional tariffs may follow, further incentivizing supply‑chain diversification. Companies must therefore integrate trade compliance, customs planning, and regulatory strategy into their broader business models to mitigate risk and capitalize on any preferential treatment offered by the new framework.